[
  {
    "ts": "2026-01-10T15:00:00+00:00",
    "headline": "RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further",
    "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-longer-term-150000728.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "28b0f146-7798-37f2-9baf-30e9fd0fb9bd",
      "content": {
        "id": "28b0f146-7798-37f2-9baf-30e9fd0fb9bd",
        "contentType": "STORY",
        "title": "RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further",
        "pubDate": "2026-01-10T15:00:00Z",
        "displayTime": "2026-01-10T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f7ca4f8eff29cf0e76b3c640a2bf4a8c",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/26.EdIzInRqGRll7JfLqfA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f7ca4f8eff29cf0e76b3c640a2bf4a8c.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9MfVRsHpmhZWDOHbB0NTJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7ca4f8eff29cf0e76b3c640a2bf4a8c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-longer-term-150000728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-longer-term-150000728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T13:59:36+00:00",
    "headline": "The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth",
    "summary": "Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady",
    "url": "https://247wallst.com/investing/2026/01/10/the-glp-1-blockbuster-maker-widens-its-lead-as-the-diversified-healthcare-giant-posts-steady-growth/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4286f150-cee5-3352-8c54-a4e41c0b0218",
      "content": {
        "id": "4286f150-cee5-3352-8c54-a4e41c0b0218",
        "contentType": "STORY",
        "title": "The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth",
        "description": "",
        "summary": "Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady",
        "pubDate": "2026-01-10T13:59:36Z",
        "displayTime": "2026-01-10T13:59:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/9fec819aa20ef9e5ca12ffbeabcc0431",
          "originalWidth": 1366,
          "originalHeight": 767,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lLLSB_dvHOZt9LeIdTXAPw--~B/aD03Njc7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/9fec819aa20ef9e5ca12ffbeabcc0431.cf.webp",
              "width": 1366,
              "height": 767,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D2kRvsgJO9CzOGb_dV46sQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/9fec819aa20ef9e5ca12ffbeabcc0431.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/10/the-glp-1-blockbuster-maker-widens-its-lead-as-the-diversified-healthcare-giant-posts-steady-growth/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/glp-1-blockbuster-maker-widens-135936482.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]